Related Experiment Video
Updated: Apr 5, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
6.2K
Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do?
Tareq Kass-Hout1, Yazan J Alderazi1, Krishna Amuluru1
1Department of Neurosurgery and Neuroscience, Rutgers University School of Medicine, Newark, N.J., USA.
Interventional Neurology
|August 18, 2015
Summary
Platelet function testing did not significantly alter neurointerventional procedure outcomes. While responders showed a trend toward better functional outcomes, further randomized trials are needed to confirm the utility of VerifyNow antiplatelet testing.
Area of Science:
- Neurointerventional Surgery
- Cardiovascular Medicine
- Clinical Trials
Background:
- Platelet function testing in neurointerventional procedures remains controversial.
- Understanding patient response to antiplatelet therapy is crucial for optimizing outcomes.
Purpose of the Study:
- To compare clinical outcomes between antiplatelet responders and nonresponders.
- To evaluate the utility of VerifyNow (VN) testing in neurointerventional procedures.
Main Methods:
- Retrospective analysis of 37 patients undergoing neurointerventional stenting.
- Patients categorized as responders or nonresponders based on preprocedural aspirin (ASA) and clopidogrel VN assays.
- Comparison of functional outcomes (modified Rankin Scale) and procedural complications.
Main Results:
- No significant difference in combined complication rates between responder and nonresponder groups.
- A trend towards higher good functional outcomes (90-day mRS 0-2) was observed in the responder group (100% vs. 80%).
Conclusions:
- VerifyNow antiplatelet function testing did not significantly alter clinical outcomes in neurointerventional procedures.
- Larger randomized trials are necessary to clarify the role of antiplatelet testing in this patient population.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:27Peripheral Artery Disease III: Interprofessional Care
586
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
586
01:27Coronary Artery Disease V: Interprofessional Care
418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
01:26Angina IV: Management
428
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
428
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589